clinical trial · NCT06803823
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
Ono Pharmaceutical Co., Ltd.·phase2·recruiting·n = 90
Agitation Associated With Alzheimer's Disease DementiaONO-2020Placebo
brief summary
To evaluate the efficacy and safety of ONO-2020 in patients with agitation associated with Alzheimer's Disease dementia in Japan.
started
May 1, 2025
primary completion
Dec 31, 2026
completion
Mar 31, 2027
last updated
May 12, 2026
official title
A Phase 2a, Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol